Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) (ALLO)

Allopregnanolone is an endogenous pregnane steroid synthesized from progesterone primarily within the nervous system acting as a potent positive allosteric modulator at γ‑aminobutyric acid type A receptors. It binds specifically at β2–α1 subunit interfaces within their transmembrane domains stabilizing open-channel conformations that enhance chloride ion influx resulting in increased neuronal inhibition. This mechanism underlies its anxiolytic, anti-stress, anticonvulsant, antidepressant properties observed both physiologically during hormonal fluctuations such as pregnancy/postpartum periods and pathologically across various neurological conditions including postpartum depression where exogenous administration improves symptoms dramatically. Beyond classical genomic steroid hormone actions mediated by nuclear receptors influencing gene transcription over hours/days timescale, allopregnanolone exerts rapid non-genomic neuromodulatory actions altering neuronal excitability within seconds/minutes. It also promotes neural progenitor cell proliferation contributing potentially to repair mechanisms after injury. Its synthesis involves enzymatic conversion from progesterone via intermediates catalyzed by enzymes like 5α-reductase followed by reduction steps forming this active metabolite. Therapeutically it has been developed into brexanolone administered intravenously for postpartum depression treatment demonstrating rapid efficacy likely linked directly to restoration/enhancement of deficient endogenous neurosteroid tone impacting mood-regulating circuits involving hypothalamus-pituitary-adrenal axis regulation through CRH neuron inhibition mediated by δ-subunit containing extrasynaptic GABAA receptors. Despite promising benefits its clinical use faces pharmacokinetic limitations prompting ongoing research into synthetic analogues with improved bioavailability suitable for oral administration aiming also toward broader indications including epilepsy syndromes linked hormonally influenced seizure susceptibility such as catamenial epilepsy.[1][2][3][4][5][6][8]

Other names

Brexanolone (USAN, trade name Zulresso)5α-Pregnan-3α-ol-20-one3α,5α-Tetrahydroprogesterone (3α,5α-THP)ALLOPSAGE-547SGE-102

Drugs targeting allopregnanolone’s pathway primarily act via: - Positive allosteric modulation at β2–α1 subunit interfaces within the transmembrane domain of the GABA_A receptor enhancing chloride channel opening upon endogenous ligand binding leading to increased inhibitory neurotransmission. The C3 hydroxyl group forms critical hydrogen bonds essential for activity. - At low nanomolar concentrations enhances natural ligand action; at higher micromolar doses can directly gate the channel. This potentiation stabilizes agonist binding preventing dissociation thereby increasing overall inhibitory tone in CNS neurons. These actions result in anxiolytic, anticonvulsant, antidepressant effects among others [2][4][6].